Annals of Hematology

, Volume 90, Issue 4, pp 441–446

Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis

  • Mehdi Khellaf
  • Jean-Gabriel Le Moine
  • Priscille Poitrinal
  • Camille Francesconi
  • Albert Haddad
  • Philippe Bierling
  • Marc Michel
  • Laurent Eckert
  • Robert Launois
  • Bertrand Godeau
Original Article

DOI: 10.1007/s00277-010-1087-x

Cite this article as:
Khellaf, M., Le Moine, JG., Poitrinal, P. et al. Ann Hematol (2011) 90: 441. doi:10.1007/s00277-010-1087-x

Abstract

This study aims to report resource utilisation and annual cost for chronic immune thrombocytopenia (ITP) patients enrolled consecutively and followed for 1 year. A single-centre, single-arm, retrospective 1-year observational cohort study of adult patients with chronic ITP from a French hospital was conducted. Healthcare resource utilisation and mean cost per patient (with 95% confidence intervals) were estimated for the whole group. Patients requiring at least one hospitalisation formed subgroup 1. Patients with the most severe category of disease formed subgroup 2 [defined as hospitalised patients with ≥1 immunoglobulin (IVIg) infusion (usually reserved for those with bleeding score >8)]. Fifty-seven patients (42F/15M) with a mean age of 48 years (SD = 19) at ITP diagnosis were studied. Mean platelet count at diagnosis was \( {28}\pm {26} \times {1}{0^9}/{\hbox{L}} \). Mean duration of ITP was 3.1 years (SD = 2); eight patients had undergone splenectomy at baseline. Subgroup 1 included 27 patients who were hospitalised (full hospitalisation, n = 23; and/or day hospitalisation, n = 8). Of those, 12 patients received at least one IVIg infusion during hospitalisation (subgroup 2). Total mean cost per patient for the 1-year study period was €7,293 (95% CI = 3,369–13,584) for the whole group, €15,334 (95% CI = 7,876–27,459) for subgroup 1 and €26,581 (95% CI = 12,241–50,578) for subgroup 2. IVIg accounted for 33% of costs for subgroup 1 and up to 43% of costs for patients with more severe disease (subgroup 2). Management of adults with chronic ITP is costly in France, especially for patients with severe disease. IVIg use was a major cost driver.

Keywords

Immune thrombocytopeniaCost of illnessResource utilisation

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Mehdi Khellaf
    • 1
  • Jean-Gabriel Le Moine
    • 2
  • Priscille Poitrinal
    • 3
  • Camille Francesconi
    • 2
  • Albert Haddad
    • 3
  • Philippe Bierling
    • 1
  • Marc Michel
    • 1
  • Laurent Eckert
    • 2
  • Robert Launois
    • 2
  • Bertrand Godeau
    • 1
  1. 1.Service de Médecine Interne, Centre Hospitalier Universitaire, Hôpital Henri Mondor, Assistance-Publique Hôpitaux de ParisUniversité Paris 12CréteilFrance
  2. 2.Réseau d’Evaluation en Economie de la SantéParisFrance
  3. 3.AMGEN (Europe) GmbHZugSwitzerland